Clinical trial

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

NCT02967133

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Nivolumab Normalized identity: nivolumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention nab-paclitaxel Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2016-12-01

PhasePHASE2

Conditions

Non-Small-Cell Lung Cancer Metastaticunresolved

Non-Small Cell Carcinoma of Lung, TNM Stage 4unresolved

Nonsmall Cell Lung Cancerverified · MONDO: tumor suppressor gene on chromosome 11

Non Small Cell Lung Cancer Recurrentunresolved

Interventions

NivolumabDRUG · verified · RxNorm: nivolumab

nab-paclitaxelDRUG

Sponsors & collaborators

Alliance Foundation Trials, LLC.lead sponsor

Celgene Corporationcollaborator

Bristol-Myers Squibbcollaborator

Mapped research locations

St LouisMissouri, United States1 OmahaNebraska, United States1 Saint Louis ParkMinnesota, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02967133 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.